Scarica l'app Stockscreener
27.39
0.70%
0.19
Dopo l'orario di chiusura:
28.00
0.61
+2.23%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IMVT Giù?
Forum
Previsione
Immunovant Inc Borsa (IMVT) Ultime notizie
Assessing Immunovant (IMVT) Valuation As Shares Deliver A 25% One Year Return - Yahoo Finance
What are Immunovant Inc.’s earnings expectationsOil Prices & Risk Managed Investment Strategies - mfd.ru
Aberdeen Group plc Has $15.83 Million Stock Position in Immunovant, Inc. $IMVT - MarketBeat
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT) - PR Newswire
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
10:48 ETSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT) - Longbridge
Will Immunovant Inc. stock recover faster than marketTrade Analysis Report & Stepwise Swing Trade Plans - mfd.ru
What are analysts’ price targets for Immunovant Inc.Quarterly Trade Report & Capital Efficient Trading Techniques - mfd.ru
Technical Reactions to IMVT Trends in Macro Strategies - Stock Traders Daily
Why hedge funds are buying Immunovant Inc. stockMarket Trend Summary & Real-Time Volume Spike Alerts - mfd.ru
FY2026 EPS Forecast for Immunovant Increased by Analyst - MarketBeat
FY2030 EPS Estimates for Immunovant Raised by HC Wainwright - MarketBeat
Is now the right time to enter Immunovant Inc.Weekly Gains Report & Trade Opportunity Analysis Reports - mfd.ru
Immunovant shares climb 7% as fiscal Q3 loss comes in better than expected - MSN
Immunovant (IMVT) Gets a Buy from Oppenheimer - The Globe and Mail
Immunovant (NASDAQ:IMVT) Given Buy Rating at HC Wainwright - MarketBeat
Immunovant stock hits all-time high at 27.87 USD By Investing.com - Investing.com Australia
Immunovant Rides Brepocitinib Momentum Into 2026 - TipRanks
IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus - Finviz
Immunovant stock hits all-time high at 27.87 USD - Investing.com
Immunovant (NASDAQ:IMVT) Hits New 12-Month High After Earnings Beat - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Immunovant (IMVT) and Roivant Sciences (ROIV) - The Globe and Mail
All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy - MSN
A Look At Immunovant (IMVT) Valuation After Trial Progress Updates And Extended Cash Runway - Yahoo Finance
Immunovant, Inc. (NASDAQ:IMVT) Q3 2026 Earnings Call Transcript - Insider Monkey
Immunovant Inc (IMVT) Shares Surge 12.4% on Q3 Earnings Beat, Pipeline Milestones - AlphaStreet News
Does Immunovant’s (IMVT) Narrower Quarterly Per‑Share Loss Reframe Its Long‑Term Risk‑Reward Equation? - simplywall.st
Decoding Immunovant Inc (IMVT): A Strategic SWOT Insight - GuruFocus
Earnings call transcript: Immunovant beats Q3 2026 EPS expectations, stock surges - Investing.com Nigeria
Immunovant (NASDAQ:IMVT) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat
Earnings call transcript: Immunovant beats Q3 2026 EPS expectations, stock surges By Investing.com - Investing.com South Africa
IMVT: Brepocitinib delivered strong phase 2 efficacy in cutaneous sarcoidosis, advancing to phase 3 - TradingView
Immunovant (NASDAQ:IMVT) Shares Gap Up Following Strong Earnings - MarketBeat
Immunovant Q3 Earnings Call Highlights - MarketBeat
IMVT: Brepocitinib phase 2 data in cutaneous sarcoidosis showed 100% high-dose response and strong safety - TradingView
Immunovant Fiscal Q3 Loss Narrows; Shares Up Pre-Bell - marketscreener.com
Immunovant shares jump 7% as Q3 loss narrows, beats estimates - Investing.com Nigeria
Immunovant shares jump 7% as Q3 loss narrows, beats estimates By Investing.com - Investing.com Australia
IMMUNOVANT ($IMVT) Releases Q3 2026 Earnings - Quiver Quantitative
Earnings Flash (IMVT) Immunovant Posts Fiscal Q3 Loss $0.61 a Share, vs. FactSet Est of $0.69 Loss - marketscreener.com
Immunovant's Q3 2025 Financial Results and Corporate Updates - TradingView
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 - The Manila Times
Immunovant (Nasdaq: IMVT) posts Q3 loss but boosts cash with $550M raise - Stock Titan
Immunovant earnings up next as Graves’ disease optimism builds By Investing.com - Investing.com Nigeria
Immunovant earnings up next as Graves’ disease optimism builds - Investing.com
Immunovant’s Upcoming Report to Spotlight Clinical Pipeline Progress - AD HOC NEWS
Immunovant, Inc. (IMVT) Stock Analysis: A Biotech Gem With 54.57% Potential Upside - DirectorsTalk Interviews
Trading the Move, Not the Narrative: (IMVT) Edition - Stock Traders Daily
Wall Street Analysts Predict a 55.04% Upside in Immunovant (IMVT): Here's What You Should Know - Finviz
0.20%
0.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):